Document Detail


Lenalidomide as a novel treatment of acute myeloid leukemia.
MedLine Citation:
PMID:  23316859     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Lenalidomide is an oral immunomodulatory drug derived from thalidomide. This drug has been approved by the Food and Drug Administration for transfusion-dependent anemia due to low-risk myelodysplastic syndromes (MDS) associated with deletion 5q abnormality with or without additional cytogenetic abnormalities and multiple myeloma in combination with dexamethasone. Trials have been conducted for its use in higher-risk MDS and acute myeloid leukemia (AML).
AREAS COVERED: The pharmacokinetic and mechanism of action are discussed and clinical studies of lenalidomide in AML are reported herein in detail. An overview of safety and tolerability is also presented.
EXPERT OPINION: Lenalidomide has clinical activity in AML with manageable toxicity. The population that would benefit from lenalidomide and optimal dose needs to be better defined. Recent trials have focused on combining lenalidomide with other agents active in MDS and AML and promising data are emerging.
Authors:
Yiming Chen; Gautam Borthakur
Related Documents :
23231399 - History and therapeutic use of mao-a inhibitors.
8891399 - Therapy of myoclonus.
24347829 - Systemic treatments for noninfectious vitreous inflammation.
20035829 - Comparison of the antiepileptic properties of transmeningeally delivered muscimol, lido...
23237189 - Synthesis, characterization and potential applications of multifunctional peo-ppopeo- m...
23920619 - Development of description framework of pharmacodynamics ontology and its application t...
20021229 - Liquid crystalline pluronic 105 pharmacogels as drug delivery systems: preparation, cha...
12740939 - Release kinetics of transforming growth factor-beta1 from fibrin clots.
16819889 - Enzyme catalysis: tool to make and break amygdalin hydrogelators from renewable resourc...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review     Date:  2013-01-15
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  22     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-11     Completed Date:  2013-07-30     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  389-97     Citation Subset:  IM    
Affiliation:
The University of Texas MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Boulevard, Unit 428, Houston, Texas 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / therapeutic use*
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Humans
Leukemia, Myeloid, Acute / drug therapy*
Thalidomide / adverse effects,  analogs & derivatives*,  therapeutic use
Grant Support
ID/Acronym/Agency:
CA016672/CA/NCI NIH HHS; P30 CA016672/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 191732-72-6/lenalidomide; 50-35-1/Thalidomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  "We have friends, for example, and he will not get a vasectomy": Imagining the self in relation to o...
Next Document:  Intrapartum polymerase chain reaction for detection of group B streptococcus colonisation.